The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Analysis of the Lysosomal Lipid Metabolism Pathway and Other Pathways, Subgroups and Stages in Parkinson’s Disease
Study Rationale: Lysosomes are cellular compartments involved in clearing molecular debris. Several genes that work in the lysosome, including GBA1, GALC, SMPD1 and others, are known to be involved in...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Targeting the Blood-brain Immune Axis to Prevent Progression of Parkinson’s Disease
Study Rationale: Recent studies suggest that the barrier that separates the brain from the rest of the body, including the blood, might become dysfunctional over the course of Parkinson’s disease (PD)...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023SUPPLEMENT | CMA as a Means to Counteract Alpha-synuclein Pathology in Non-human Primates”
Study Rationale: One of the main pathways to remove excess amounts of the alpha-synuclein protein that is linked to Parkinson’s disease (PD) is the lysosomal chaperone-mediated autophagy (CMA) pathway...
-
Lysosomal Biomarkers Program, 2023Validating Measurements of Peripheral GCase Longitudinally Under Clinical Trial Conditions
Study Rationale: An enzyme known as GCase is a key protein that stops working properly in people with Parkinson’s disease (PD). However, determining exactly how impaired the enzyme’s activity might...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Effect of SAR-CoV-2 on Experimental Parkinsonism in a Preclinical Model of Parkinson’s Disease
Study Rationale: Approximately 16.5 million people have been infected with the SARS-CoV2 virus. While primarily a respiratory virus, clinical observations indicate that in many cases, infection is...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Targeting the Blood-brain Immune Axis to Prevent Progression of Parkinson’s Disease
Study Rationale: Recent studies suggest that the barrier that separates the brain from the rest of the body, including the blood, might become dysfunctional over the course of Parkinson’s disease (PD)...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.